Cooper Companies

COO · NASDAQ

$59.12+$0.96 (+1.65%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $58.16

COO analyst rating

HoldConsensus of 15 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy5
Hold9
Underperform0
Sell1

12-month price target · 18 analysts

Average $71.07 (+20.2% upside)

Low: $59.59
Now: $59.12
High: $96.60

Upgrades and downgrades

The latest rating actions, newest first

COO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 7, 2026	Initiates	Equal-Weight	$60.00	68%
Needham	Sep 15, 2026	Maintains	Buy	$73.00	39%
Mizuho	Sep 11, 2026	Maintains	Outperform	$85.00 → $75.00	56%
William Blair	Sep 10, 2026	Downgrade	Outperform → Market Perform	—	38%
Wells Fargo	Sep 10, 2026	Maintains	Equal-Weight	$66.00 → $61.00	54%
Stifel	Sep 10, 2026	Maintains	Buy	$85.00 → $70.00	55%
Citigroup	Sep 10, 2026	Maintains	Neutral	$80.00 → $60.00	60%
Piper Sandler	Sep 10, 2026	Downgrade	Overweight → Neutral	$86.00 → $59.00	43%
JP Morgan	Sep 10, 2026	Maintains	Neutral	$71.00 → $58.00	56%
UBS	Sep 10, 2026	Maintains	Neutral	$75.00 → $66.00	43%

The case for and against

Updated Oct 14, 2026

Bull case

Cooper Companies is well positioned to compound growth through its two balanced segments, with CooperVision’s broad contact lens franchise and roughly one fourth of the US market providing durable scale, while CooperSurgical adds diversification through fertility, reproductive care, and the only hormone-free IUD in the US. The company’s operating performance supports the bullish view, as gross margin reached 68.1% and operating margin expanded to 27.5% while sales and EPS beat consensus, showing that expense leverage and mix can offset softer end-market conditions. Further upside comes from mid-single digit organic growth potential, a recovering fertility market, ongoing strategic review interest in CSI, and heavier share repurchases that could enhance EPS growth as debt and interest expense decline.

Bear case

Cooper Companies is facing a weakening fundamental setup as revenue missed consensus at $1.066B and management cut FY26 guidance to $4.229-$4.252B revenue and $4.51-$4.55 EPS, signaling softer demand than previously expected. CooperVision is the main concern, with 0% organic growth, a likely 110 bps share loss, and channel inventory de-stocking in the US plus APAC weakness that offset only modest strength in EMEA. CooperSurgical also slowed to 3% organic growth, with softer capital equipment sales and flat Paragard revenue, while higher FY27 tax rates to 17.5% add further pressure to earnings leverage.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.